Stability-indicating HPTLC determination of imatinib mesylate in bulk drug and pharmaceutical dosage form
- 17 January 2007
- journal article
- research article
- Published by Elsevier BV in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 43 (2), 722-726
- https://doi.org/10.1016/j.jpba.2006.07.022
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- RETRACTED: Kinase inhibitors and airway inflammationEuropean Journal of Pharmacology, 2006
- Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samplesJournal of Chromatography B, 2004
- Reversed-phase liquid chromatography analysis of imatinib mesylate and impurity product in Glivec® capsulesJournal of Chromatography B, 2004
- Gastrointestinal Stromal Tumors Respond to Tyrosine Kinase-targeted Therapy.Current Treatment Options in Gastroenterology, 2004
- A validated LC method for imatinib mesylateJournal of Pharmaceutical and Biomedical Analysis, 2003
- Liquid chromatographic–mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasmaJournal of Chromatography B, 2003
- Quantification of the anti-leukemia drug STI571 (Gleevec™) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometryJournal of Pharmaceutical and Biomedical Analysis, 2002
- Stability indicating HPTLC method for the simultaneous determination of pseudoephedrine and cetirizine in pharmaceutical formulationsJournal of Pharmaceutical and Biomedical Analysis, 2001
- Stability indicating HPTLC determination of Trimetazidine as bulk drug and in pharmaceutical formulationsJournal of Pharmaceutical and Biomedical Analysis, 2001
- Stability indicating HPTLC determination of timolol maleate as bulk drug and in pharmaceutical preparationsJournal of Pharmaceutical and Biomedical Analysis, 2000